AMRX vs SUPN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SUPN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRX and SUPN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRX and SUPN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

Full AMRX guide

Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. The commercial model is straightforward specialty pharma. Supernus owns or licenses the products, runs its own US sales force calling on neurologists and psychiatrists, and books the revenue net of rebates and channel discounts. Its growth engine is Qelbree, a non-stimulant ADHD treatment that did ~$89 million in net sales in the second quarter of 2026 (up ~15%), alongside GOCOVRI for Parkinson's dyskinesia (~$38 million), ONAPGO, a continuous subcutaneous apomorphine infusion launched in 2025 (~$14 million), and collaboration revenue from ZURZUVAE for postpartum depression (~$35 million), which Supernus acquired when it bought Sage Therapeutics in mid-2025 and which it splits 50/50 with Biogen. Working against that are the legacy products: Trokendi XR and Oxtellar XR each fell ~25% year over year, APOKYN fell ~51%, and other older products fell ~71%.

Full SUPN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRX drivers: Specialty and biosimilar mix shift; Kashiv BioSciences acquisition.
• SUPN drivers: Qelbree as the volume anchor in ADHD; ONAPGO and the device-delivered Parkinson's franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amneal carries meaningful leverage, with total debt of about $2.8 billion against about $131 million of cash at the end of June 2026, plus an added $350 million term loan for Kashiv, which amplifies both upside and downside and limits financial flexibility. For SUPN, the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRX if you believe its drivers more; SUPN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRX and SUPN guides.

AMRX. After nearly doubling over the past year, Amneal trades at about 39 times trailing GAAP earnings but about 16 times 2027 consensus EPS of roughly $1.19, a gap that reflects fast-rising profits from a low base. EV/EBITDA is about 13 times, and enterprise value sits well above market cap because of roughly $2.8 billion of debt. The valuation leans on the specialty and biosimilar mix shift continuing after the Kashiv close.

SUPN. At ~$38.44 per share the market values Supernus at about 2.7 times trailing sales and under 9 times consensus 2027 earnings, a discount to profitable specialty pharma peers that reflects legacy-product decay and, above all, the pending merger. The GAAP loss is largely non-cash, coming from a ~$55 million APOKYN impairment and ~$25 million per quarter of intangible amortization. Because the Indivior exchange ratio is fixed at 1.5401 shares and closing is expected on November 2, 2026, the practical value of a Supernus share now moves with Indivior's price far more than with Supernus's own results.

Headline figures (approximate, October 2026): AMRX shows revenue (ttm) ~$3.1B, q2 2026 net revenue ~$796M (up ~10% YoY), q2 2026 adjusted ebitda ~$206M (up ~12% YoY), q2 2026 adjusted eps ~$0.30 (vs ~$0.23 expected); SUPN shows revenue (ttm) ~$830M, q2 2026 revenue ~$219M, up ~32% year over year; adjusted EPS ~$0.53 vs ~$0.51 consensus, fy2026 revenue guidance ~$860M to ~$890M, fy2026 adjusted operating earnings guidance ~$150M to ~$180M.

AMRX and SUPN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRX and SUPN exposure against your real portfolio. It is not an investment adviser.